FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965228282> ?p ?o ?g. }

• W2965228282 endingPage "109" @default.
• W2965228282 startingPage "101" @default.
• W2965228282 abstract "Background Previous studies have suggested that biologic therapy for psoriasis might relate to body weight gain. Objective To assess the changes in body weight and body mass index (BMI) in psoriasis patients after receiving various biologics. Methods We conducted a systematic review and network meta-analysis to evaluate the changes in body weight and BMI in psoriasis patients receiving biologics. On March 1, 2019, we searched Medline, Embase, and Cochrane Central Register of Controlled Trials for relevant studies. The Newcastle-Ottawa scale was used to assess the risk of bias. Results We included 6 studies with 862 psoriasis patients. Compared with conventional systemic treatments, treatment with tumor necrosis factor α inhibitors was associated with a significant increase in body weight (mean difference 1.40 kg, 95% confidence interval 0.88-1.93 kg) and BMI (0.39 kg/m2, 95% confidence interval 0.24-0.54 kg/m2). In contrast, no significant increase in body weight or BMI was found among patients receiving anti-interleukin (IL)-12/23 or anti-IL-17 biologics. Limitations Only 1 study reported body weight and BMI for patients receiving the anti-IL-17 biologic. Conclusion Tumor necrosis factor α inhibitor treatment appears to be associated with an increase in body weight and BMI, and treatment with anti-IL-12/23 and anti-IL-17 biologics do not. This association should be considered before initiating biologics for overweight and obese patients. Previous studies have suggested that biologic therapy for psoriasis might relate to body weight gain. To assess the changes in body weight and body mass index (BMI) in psoriasis patients after receiving various biologics. We conducted a systematic review and network meta-analysis to evaluate the changes in body weight and BMI in psoriasis patients receiving biologics. On March 1, 2019, we searched Medline, Embase, and Cochrane Central Register of Controlled Trials for relevant studies. The Newcastle-Ottawa scale was used to assess the risk of bias. We included 6 studies with 862 psoriasis patients. Compared with conventional systemic treatments, treatment with tumor necrosis factor α inhibitors was associated with a significant increase in body weight (mean difference 1.40 kg, 95% confidence interval 0.88-1.93 kg) and BMI (0.39 kg/m2, 95% confidence interval 0.24-0.54 kg/m2). In contrast, no significant increase in body weight or BMI was found among patients receiving anti-interleukin (IL)-12/23 or anti-IL-17 biologics. Only 1 study reported body weight and BMI for patients receiving the anti-IL-17 biologic. Tumor necrosis factor α inhibitor treatment appears to be associated with an increase in body weight and BMI, and treatment with anti-IL-12/23 and anti-IL-17 biologics do not. This association should be considered before initiating biologics for overweight and obese patients." @default.
• W2965228282 created "2019-08-13" @default.
• W2965228282 creator A5009926815 @default.
• W2965228282 creator A5025488975 @default.
• W2965228282 creator A5027260317 @default.
• W2965228282 creator A5068719988 @default.
• W2965228282 date "2020-01-01" @default.
• W2965228282 modified "2023-10-09" @default.
• W2965228282 title "Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis" @default.
• W2965228282 cites W1524805008 @default.
• W2965228282 cites W1537972189 @default.
• W2965228282 cites W1617328014 @default.
• W2965228282 cites W1742137696 @default.
• W2965228282 cites W1920164691 @default.
• W2965228282 cites W1964795085 @default.
• W2965228282 cites W1983141987 @default.
• W2965228282 cites W2005422908 @default.
• W2965228282 cites W2010699829 @default.
• W2965228282 cites W2012735968 @default.
• W2965228282 cites W2022223573 @default.
• W2965228282 cites W2033584051 @default.
• W2965228282 cites W2041510403 @default.
• W2965228282 cites W2042583590 @default.
• W2965228282 cites W2045108975 @default.
• W2965228282 cites W2047354818 @default.
• W2965228282 cites W2048161634 @default.
• W2965228282 cites W2064645845 @default.
• W2965228282 cites W2072844086 @default.
• W2965228282 cites W2073601928 @default.
• W2965228282 cites W2084433985 @default.
• W2965228282 cites W2089781115 @default.
• W2965228282 cites W2090043000 @default.
• W2965228282 cites W2091808438 @default.
• W2965228282 cites W2104883144 @default.
• W2965228282 cites W2111687706 @default.
• W2965228282 cites W2116475791 @default.
• W2965228282 cites W2122609353 @default.
• W2965228282 cites W2128911005 @default.
• W2965228282 cites W2152788537 @default.
• W2965228282 cites W2169596216 @default.
• W2965228282 cites W2193504330 @default.
• W2965228282 cites W2324248975 @default.
• W2965228282 cites W2331712921 @default.
• W2965228282 cites W2346094900 @default.
• W2965228282 cites W2508209283 @default.
• W2965228282 cites W2591245715 @default.
• W2965228282 cites W2606304149 @default.
• W2965228282 cites W2606426055 @default.
• W2965228282 cites W2625513611 @default.
• W2965228282 cites W2762883381 @default.
• W2965228282 cites W2810745227 @default.
• W2965228282 cites W2884929624 @default.
• W2965228282 cites W2898603313 @default.
• W2965228282 cites W3145786645 @default.
• W2965228282 cites W4243747196 @default.
• W2965228282 doi "https://doi.org/10.1016/j.jaad.2019.07.103" @default.
• W2965228282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31400455" @default.
• W2965228282 hasPublicationYear "2020" @default.
• W2965228282 type Work @default.
• W2965228282 sameAs 2965228282 @default.
• W2965228282 citedByCount "27" @default.
• W2965228282 countsByYear W29652282822020 @default.
• W2965228282 countsByYear W29652282822021 @default.
• W2965228282 countsByYear W29652282822022 @default.
• W2965228282 countsByYear W29652282822023 @default.
• W2965228282 crossrefType "journal-article" @default.
• W2965228282 hasAuthorship W2965228282A5009926815 @default.
• W2965228282 hasAuthorship W2965228282A5025488975 @default.
• W2965228282 hasAuthorship W2965228282A5027260317 @default.
• W2965228282 hasAuthorship W2965228282A5068719988 @default.
• W2965228282 hasBestOaLocation W29652282821 @default.
• W2965228282 hasConcept C126322002 @default.
• W2965228282 hasConcept C147583825 @default.
• W2965228282 hasConcept C16005928 @default.
• W2965228282 hasConcept C2777011040 @default.
• W2965228282 hasConcept C2780221984 @default.
• W2965228282 hasConcept C2780320433 @default.
• W2965228282 hasConcept C2780564577 @default.
• W2965228282 hasConcept C2780586474 @default.
• W2965228282 hasConcept C3017894415 @default.
• W2965228282 hasConcept C44249647 @default.
• W2965228282 hasConcept C511355011 @default.
• W2965228282 hasConcept C544821477 @default.
• W2965228282 hasConcept C71924100 @default.
• W2965228282 hasConceptScore W2965228282C126322002 @default.
• W2965228282 hasConceptScore W2965228282C147583825 @default.
• W2965228282 hasConceptScore W2965228282C16005928 @default.
• W2965228282 hasConceptScore W2965228282C2777011040 @default.
• W2965228282 hasConceptScore W2965228282C2780221984 @default.
• W2965228282 hasConceptScore W2965228282C2780320433 @default.
• W2965228282 hasConceptScore W2965228282C2780564577 @default.
• W2965228282 hasConceptScore W2965228282C2780586474 @default.
• W2965228282 hasConceptScore W2965228282C3017894415 @default.
• W2965228282 hasConceptScore W2965228282C44249647 @default.
• W2965228282 hasConceptScore W2965228282C511355011 @default.
• W2965228282 hasConceptScore W2965228282C544821477 @default.
• W2965228282 hasConceptScore W2965228282C71924100 @default.
• W2965228282 hasIssue "1" @default.

• next